<DOC>
	<DOCNO>NCT01370694</DOCNO>
	<brief_summary>This study evaluate safety , pharmacokinetics , anti-tumor activity MK-8808 combination cyclophosphamide , vincristine , prednisolone ( CVP ) , single agent , participant B-lymphocyte antigen cluster differentiation 20 ( CD20 ) -positive follicular lymphoma prior chemotherapy . The primary study hypothesis MK-8808 safe well tolerate combination CVP single agent .</brief_summary>
	<brief_title>Study MK-8808 Participants With Follicular Lymphoma ( MK-8808-001 )</brief_title>
	<detailed_description>The study terminate early Sponsor due business reason . All participant discontinue MK-8808 + CVP , could continue receive maintenance therapy MabThera™ ( rituximab ) per standard care .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Histological diagnosis CD20positive follicular lymphoma , Grade 1 , 2 , 3a ( World Health Organization [ WHO ] 2008 classification ) base excisional incisional lymph node biopsy bone marrow biopsy . Ann Arbor Stage III IV disease . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Life expectancy &gt; 3 month expect need immediate intervention treat lifethreatening complication . Adequate organ function . Participants must agree use adequate method contraception start first dose study drug 12 month ( female ) 90 day ( male ) last dose study drug . Exclusion criterion : Histological Grade 3b &gt; 50 % diffuse architectural pattern . Circulating malignant cell &gt; 25,000/mm^3 Presence history central nervous system ( CNS ) disease ( either CNS lymphoma lymphomatous meningitis ) . Prior treatment chemotherapy , rituximab , antiCD20 compound , type anticancer compound . Radiotherapy within 2 month prior Cycle 1 Day 1 . Current participation participate study investigational compound within 30 day prior Cycle 1 Day 1 . Concomitant disease require continuous therapy prednisone dose &gt; 20 mg per day . Any medical contraindication prednisolone dose CVP regimen . Poorly control diabetes mellitus , define institutional local standard . Grade &gt; 2 peripheral neuropathy . Has one following : 1. human immunodeficiency virus ( HIV ) positive 2. Hepatitis B surface antigen positive ( HBsAg+ ) positive antibody Hepatitis B core antigen ( antiHBcAg+ ) 3. antibody Hepatitis C virus Has one following : 1 . Active tuberculosis base institutional diagnostic criterion local practice guideline . 2 . Evidence tuberculosis infection base chest Xray ( CXR ) compute tomography ( CT ) scan perform within 3 month dose . 3 . History tuberculosis infection . Major surgical procedure within 4 week prior Cycle 1 Day 1 . Regular use ( include `` recreational '' use ) illicit drug recent history ( within last year ) drug alcohol abuse dependence . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>